ImmunoGen Said Regarding AbbVie Merger, The 30-day Waiting Period Imposed By The HSR Act In Connection With The Merger Expired At 11:59 P.M. On February 7, 2024, Without Action By FTC; Expects Closing Of Transactions To Occur On Or About February 12
Portfolio Pulse from Charles Gross
ImmunoGen announced that the 30-day waiting period required by the HSR Act for its merger with AbbVie expired without FTC action, expecting the transaction to close around February 12, 2024.
February 08, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's pending merger with ImmunoGen is expected to close around February 12, 2024, following the expiration of the HSR Act waiting period without FTC action.
The successful expiration of the HSR Act waiting period without FTC intervention is a crucial step forward for AbbVie's acquisition of ImmunoGen. This regulatory clearance is likely to be seen as a positive development by the market, potentially leading to a short-term positive impact on AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
ImmunoGen's merger with AbbVie is expected to close around February 12, 2024, after passing the HSR Act waiting period without FTC intervention.
The expiration of the HSR Act waiting period without FTC action is a significant positive development for ImmunoGen, indicating regulatory approval for the merger. This is likely to be viewed positively by investors, potentially leading to a short-term increase in IMGN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90